Analyses of the pharmacotherapeutic profile and treatment costs of patients treated by the specialized component of pharmaceutical care in the city of Caririaçu, Ceará

Abstract

Objectives: to analyze the pharmacotherapeutic profile and treatment costs of patients assisted by the Specialized Component of Pharmaceutical Assistance (CEAF) in a municipality in the state of Ceará. Methods: descriptive and exploratory study carried out in a small town located in the state of Ceará. Data were collected at the CEAF pharmacy, from January 2020 to January 2021, referring to patients registered in the service between June 2011 and June 2020. for all stages of the CEAF, in the National Pharmaceutical Assistance Management System (Horus), namely: registration, request, evaluation, authorization, dispensing and renewal. To determine the costs per treatment, the values described in the medication receipt forms provided by the State Department of Health were used. Data were tabulated in Microsoft Excel® and statistical analysis, of the descriptive type, was performed using the Statistical Package for Social Sciences®. Results: The sample consisted of 143 individuals, in which there was a predominance of female patients (86.0%; n=123) and aged > 50 years (78.3%; n=112). The most prevalent disease was idiopathic osteoporosis (61.7%; n=96), predominantly in women (68.1%; 91), especially in the 60 and 69 age group (61.7%; n=96). With regard to male users, the most prevalent disease was paranoid schizophrenia (48.1%; n=13). In all, 27 CEAF items were dispensed with, with emphasis on calcitriol 0.25mg; olanzapine, 5 and 10mg; atovastatin 10 and 20 mg; and quetiapine, 25, 100 and 200 mg. Most drugs belonged to CEAF group 1A (59.6%; n=16), whose financing and distribution to the states is the responsibility of the Ministry of Health. The clinical condition with the highest funding by the health system was paranoid schizophrenia, with investment of 21.2% (R$ 63,050.40) of the total in medication. Conclusion: Our findings made it possible to delineate the clinical profile and treatment costs of users assisted by CEAF. Integrating clinical, epidemiological and drug management knowledge is important to  overcome adversities and adequately meet the health needs of the population.